1. Expert Q&A: Benefits - Weds 23 October, 3-4pm

    Our next expert Q&A will be on the topic of benefits. It will be hosted by Lauren from our Knowledge Services team. She'll be answering your questions on Wednesday 23 October between 3-4pm.

    You can either post your question >here< or email them to us at talkingpoint@alzheimers.org.uk and we'll be happy to ask them on your behalf.

£68m partnership with pharmaceutical companies to battle dementia

Discussion in 'Dementia-related news and campaigns' started by jimbo 111, Mar 18, 2015.

  1. jimbo 111

    jimbo 111 Registered User

    Jan 23, 2009
    5,082
    North Bucks
    Hunt announces £68m partnership with pharmaceutical companies to battle dementia



    Health secretary Jeremy Hunt has announced a £68m fund to help research new treatments for dementia through a global partnership between major pharmaceutical companies and the UK government.
    Biogen, GlaxoSmithKline, Johnson and Johnson, Lilly and Pfizer have all committed in principle to investing in the project alongside Alzheimer’s Research UK.
    The Government has worked with the financial services company JP Morgan to structure the Dementia Discovery Fund as a means of financing dementia research.
    The funds committed by investors today include £15m that the Government announced in the autumn last year.
    Speaking at a World Health Organisation conference on global action against dementia, Mr Hunt said: ‘The new fund is a unique collaboration, bringing together the combined expertise of government, financial, industry and charity partners


    Read more

    http://www.pulsetoday.co.uk/clinica...battle-dementia/20009475.article#.VQl4_hofxI0
     

Share This Page

  1. This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
    By continuing to use this site, you are consenting to our use of cookies.
  1. This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
    By continuing to use this site, you are consenting to our use of cookies.